Candidemia in the in-patient setting: Treatment options and economics

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 11, 2007, Pages 1643-1650

  Gagne, Joshua J ^a   Goldfarb, Neil I ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Antifungal; Candida; Candidemia; Cost; Pharmacoeconomic

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; VORICONAZOLE;

ABNORMAL LABORATORY RESULT; CANDIDEMIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DEATH; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; HYPOKALEMIA; LOADING DRUG DOSE; NEPHROTOXICITY; NONHUMAN; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; UNITED STATES; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDIASIS; COST-BENEFIT ANALYSIS; FUNGEMIA; HOSPITALIZATION; HUMANS;

EID: 34548130047     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.11.1643     Document Type: Review

References (54)

1. RANGEL-FRAUSTO MS, WIBLIN T, BLUMBERG HM et al.: National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin. Infect. Dis. (1999) 29:253-258.
2. SNYDMAN DR: Shifting patterns in the epidemiology of nosocomial Candida infections. Chest (2003) 123:S500-S503.
3. BECK-SAGUE C, JARVIS WR: Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National nosocomial infections surveillance system. J. Infect. Dis. (1993) 167:1247-1251.
4. EDMOND MB, WALLACE SE, MCCLISH DK, PFALLER MA, JONES RN, WENZEL RP: Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin. Infect. Dis. (1999) 29:239-244.
5. JARVIS WR: Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin. Infect. Dis. (1995) 20:1526-1530.
6. PAPPAS PG, REX JH, SOBEL JD et al.: Guidelines for treatment of candidiasis. Clin. Infect. Dis. (2004) 38:161-189.
7. WEY SB, MORI M, PFALLER MA, WOOLSON RF, WENZEL RP: Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch. Intern. Med. (1988) 148:2642-2645.
8. WENZEL RP: Nosocomial candidemia: risk factors and attributable mortality. Clin. Infect. Dis. (1995) 20:1531-1534.
9. CHENG MF, YANG YL, YAO TJ et al.: Risk factors for fatal candidemia caused by Candida albicans and non-albicans Candida species. BMC Infect. Dis. (2005) 5:22.
10. ZAOUTIS TE, ARGON J, CHU J, BERLIN JA, WALSH TJ, FEUDTNER C: The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin. Infect. Dis. (2005) 41:1232-1239.
11. RENTZ AM, HALPERN MT, BOWDEN R: The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin. Infect. Dis. (1998) 27:781-788.
12. MORGAN J, MELTZER MI, PLIKAYTIS BD et al.: Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect. Control. Hosp. Epidemiol. (2005) 26:540-547.
13. GUDLAUGSSON O, GILLESPIE S, LEE K et al.: Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. (2003) 37:1172-1177.
14. GAGNE JJ, BREITBART RE, MAIO V et al.: Costs associated with candidemia in a hospital setting. P&T (2006) 31:586-589, 591, 619.
15. MCNEIL MM, NASH SL, HAJJEH RA et al.: Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin. Infect. Dis. (2001) 33:641-647.
16. PITTET D, TARARA D, WENZEL RP: Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA (1994) 271:1598-1601.
17. PFALLER MA, JONES RN, MESSER SA, EDMOND MB, WENZEL RP: National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn. Microbiol. Infect. Dis. (1998) 31:327-332.
18. DIEKEMA DJ, MESSER SA, BRUEGGEMANN AB et al.: Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J. Clin. Microbiol. (2002) 40:1298-1302.
19. REX JH, COOPER CR Jr, MERZ WG, GALGIANI JN, ANAISSIE EJ: Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob. Agents Chemother. (1995) 39:906-909.
20. NGUYEN MH, CLANCY CJ, YU VL et al.: Do in vitro susceptibility data predict the microbiologic response to amphoteticin B? Results of a prospective study of patients with Candida fungemia. J. Infect. Dis. (1998) 177:425-430.
21. MARCO F, PFALLER MA, MESSER SA, JONES RN: Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn. Microbiol. Infect. Dis. (1998) 32:33-37.
22. ESPINEL-INGROFF A: Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. (1998) 36:2950-2956.
23. BEN-ABRAHAM R, KELLER N, TEODOROVITCH N et al.: Predictors of adverse outcome from candidal infection in a tertiary care hospital. J. Infect. (2004) 49:317-323.
24. IBRAHIM EH, SHERMAN G, WARD S, FRASER VJ, KOLLEF MH: The influence of inadequate antimicrobial treatment of bloodstream infectiom on patient outcomes in the ICU setting. Chest (2000) 118:146-155.
25. BOUZA E, SOUSA D, MUNOZ P, RODRIGUEZ-CREIXEMS M, FRON C, LECHUZ JG: Bloodstream infections: a trial of the impact of different methods of reporting positive blood culture results. Clin. Infect. Dis. (2004) 39:1161-1169.
26. GAREY KW, REGE M, PAI MP et al.: Tune to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. (2006) 43:25-31.
27. MORRELL M, FRASER VJ, KOLLEF MH: Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents Chemother. (2005) 49:3640-3645.
28. PFALLER MA, MESSER SA, HOLLIS RJ, JONES RN, DIEKEMA DJ: In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob. Agents Chemother. (2002) 46:1723-1727.
29. FISHER MA, SHEN SH, HADDAD J, TARRY WF: Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei. Antimicrob. Agents Chemother. (1989) 33:1443-1446.
30. KARYOTAKIS NC, ANAISSIE EJ, HACHEM R, DIGNANI MC, SAMONIS G: Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice. J. Infect. Dis. (1993) 168:1311-1313.
31. PFALLER MA, MESSER SA, HOLLIS RJ: Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae. Diagn. Microbiol. Infect. Dis. (1994) 20:127-133.
32. YOON SA, VAZQUEZ JA, STEFFAN PE, SOBEL JD, AKINS PA: High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance. Antimicrob. Agents Chemother. (1999) 43:836-845.
33. WINGARD JR, KUBILIS P, LEE L et al.: Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect. Dis. (1999) 29:1402-1407.
34. WALSH TJ, FINBERG RW, ARNDT C et al.: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N. Engl. J. Med. (1999) 340:764-771.
35. BATES DW, SU L, YU DT et al.: Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin. Infect. Dis. (2001) 32:686-693.
36. HIEMENZ JW, WALSH TJ: Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. (1996) 22(Suppl. 2):S133-S144.
37. REX JH, WALSH TJ, ANAISSIE EJ: Fungal infections in iatrogenically compromised hosts. Adv. Intern. Med. (1998) 43:321-371.
38. RICHARDSON K, COOPER K, MARRIOTT MS, TARBIT MH, TROKE PF, WHITTLE PJ: Discovery of fluconazole, a novel antifungal agent. Rev. Infect. Dis. (1990) 12(Suppl. 3):S267-S271.
39. REX JH, BENNETT JE, SUGAR AM et al.: A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N. Engl. J. Med. (1994) 331:1325-1330.
40. MASIA CANUTO M, GUTIERREZ RODERO F: Antifungal drug resistance to azoles and polyenes. Lancet Infect. Dis. (2002) 2:550-563.
41. MAGILL SS, SHIELDS C, SEARS CL, CHOTI M, MERZ WG: Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J. Clin. Microbiol. (2006) 44:529-535.
42. VFEND® [Package insert]. New York, NY: Pfizer, Inc. (2006).
43. ST. GERMAIN RM, ELLIS JM: Anidulafungin: an echinocandin antifungal for the treatment of Candida infection. Formulary (2006) 41:387-403.
44. BENNETT JE: Echinocandins for candidemia in adults without neutropenia. N. Engl. J. Med. (2006) 355:1154-1159.
45. KULLBERG BJ, SOBEL JD, RUHNKE M et al.: Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet (2005) 366:1435-1442.
46. REX JH, WINGARD JR, WENZEL R, HERBRECHT R, SOBEL J, EDWARDS JE Jr: The design of clinical trials that evaluate antifungal prophylaxis and combination therapy: introduction and overview. Clin. Infect. Dis. (2004) 39(Suppl. 4):S165-S169.
47. PHILLIPS P, SHAFRAN S, GARBER G et al.: Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur. J. Clin. Microbiol. Infect. Dis. (1997) 16:337-345.
48. ANAISSIE EJ, REX JH, UZUN O, VARTIVARIAN S: Predictors of adverse outcome in cancer patients with candidemia. Am. J. Med. (1998) 104:238-245.
49. NGUYEN MH, PEACOCK JE Jr, TANNER DC et al.: Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch. Intern. Med. (1995) 155:2429-2435.
50. MORA-DUARTE J, BETTS R, ROTSTEIN C et al.: Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. (2002) 347:2020-2029.
51. WALSH TJ, TEPPLER H, DONOWITZ GR et al.: Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. (2004) 351:1391-1402.
52. GUBBINS PO, PENZAK SR, POLSTON S, MCCONNELL SA, ANAISSIE E: Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients. Pharmacotherapy (2002) 22:961-971.
53. WINGARD JR, WOOD CA, SULLIVAN E, BERGER ML GERTH WC, MANSLEY EC: Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis. Clin. Ther. (2005) 27:960-969. Pharmacoeconomic comparison of caspofungin verses amphotericin B.
54. ALEXANDER BD, ASHLEY ED, RELLER LB, REED SD: Cost savings with implementation of PNA FISH testing for identification of Candida albicans in blood cultures. Diagn. Microbiol. Infect. Dis. (2006) 54:277-282.